版本:
中国

BRIEF-Teva and Celltrion report exclusive biosimilar commercial partnership

Oct 6 Teva Pharmaceutical Industries Ltd :

* Teva will pay Celltrion healthcare $160 million upfront

* Teva and Celltrion healthcare will share profit from commercialization of mab biosimilars

* Exclusive partnership to commercialize two of Celltrion's MAB biosimilar candidates in U.S. and canada

* Celltrion has responsibility for completing all clinical development and regulatory activities

* Of $160 million upfront payment, up to $60 million is refundable or creditable under certain circumstances Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐